EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024.08.26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024.08.26

Date

Title

2023-03-08

Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready

2023-02-23

2023-02-22

Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration

2023-02-10

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-10-13

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

2022-08-24

Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance

2022-08-23

Essex Bio-Technology Announces 2022 Interim Financial Results

2022-08-15

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT